Senores Pharmaceuticals Limited has informed the Exchange regarding the media release in relation to the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals posted strong Q1 FY26 (quarter ended June 30, 2025) results with consolidated total income rising 72% year-on-year to Rs. 138 crore, driven by a 69% jump in Regulated Markets revenue to Rs. 90.1 crore and a 32% rise in Emerging Markets revenue to Rs. 29 crore. EBITDA grew 60% YoY to Rs. 34.2 crore with a margin of 24.8%, while profit after tax surged 95% YoY to Rs. 21.2 crore, expanding PAT margin to 15.4%. The company launched 2 own ANDA products and received 4 ANDA approvals during the quarter, reported positive operating cash flow of Rs. 11 crore, and highlighted US tariff insulation due to local US-based manufacturing. Management reiterated growth pillars around ANDA expansion, CDMO/CMO scale-up, and Emerging Markets profitability.
Strong across-the-board growth with nearly doubled profits signals robust operational momentum and is likely to be viewed positively by investors; however, the filing is a media release accompanying already-approved results, so the direct stock impact is limited to sentiment reinforcement rather than new disclosure.